Direxion Shares ETF Trust. Holdings as of Jul 31, 2026, from Form N-PORT.
Share of net assets at the report date, for the whole fund across all share classes.
| Holding | Weight | Value | Shares or units |
|---|---|---|---|
| GOLDMAN FINANCIALCash or money market | 22.36% | $4.62M | 4,616,827 |
| N/ADO | 16.36% | $3.38M | 1 |
| DREYFUSCash or money market | 8.14% | $1.68M | 1,680,337 |
| N/ADO | 7.41% | $1.53M | 1 |
| CRINETICS PHARMACEUTICALS IN | 2.77% | $571.61K | 6,844 |
| MBX BIOSCIENCES INCMBX | 2.42% | $499.75K | 7,580 |
| ATAIBECKLEY INC | 2.16% | $446.17K | 62,140 |
| Definium Therapeutics, IncDFTX | 2.13% | $439.94K | 10,109 |
| GOLDMAN SACHS LIQ ES FD ACash or money market | 2.03% | $420.00K | 420,000 |
| AMYLYX PHARMACEUTICALS INCAMLX | 1.72% | $354.43K | 17,451 |
| ENLIVEN THERAPEUTICS INCELVN | 1.68% | $347.93K | 6,348 |
| CORCEPT THERAPEUTICS INCCORT | 1.67% | $344.27K | 3,007 |
| ALUMIS INCALMS | 1.60% | $330.78K | 11,709 |
| NUVATION BIO INCNUVB | 1.57% | $324.64K | 51,286 |
| TREVI THERAPEUTICS INCTRVI | 1.55% | $319.90K | 17,529 |
| LIQUIDIA CORPLQDA | 1.47% | $302.80K | 3,600 |
| NEKTAR THERAPEUTICSNKTR | 1.42% | $292.43K | 4,138 |
| AMNEAL PHARMACEUTICALS INCAMRX | 1.36% | $280.86K | 15,331 |
| BRISTOL-MYERS SQUIBB COBMY | 1.34% | $276.00K | 4,226 |
| EDGEWISE THERAPEUTICS INCEWTX | 1.33% | $274.27K | 7,137 |
| OMEROS CORPOMER | 1.32% | $272.65K | 23,028 |
| LIGAND PHARMACEUTICALSLGND | 1.32% | $272.30K | 947 |
| ELANCO ANIMAL HEALTH INCELAN | 1.31% | $270.82K | 10,270 |
| VERADERMICS INCMANE | 1.28% | $265.23K | 2,526 |
| PACIRA PHARMACEUTICALS INCPCRX | 1.28% | $264.87K | 10,029 |
| VIATRIS INCVTRS | 1.27% | $261.57K | 14,896 |
| JAZZ PHARMACEUTICALS PLCJAZZ | 1.25% | $258.68K | 1,023 |
| ETON PHARMACEUTICALS INCETON | 1.25% | $257.54K | 5,548 |
| MAZE THERAPEUTICS INCMAZE | 1.25% | $257.11K | 9,551 |
| MERCK & COMPANY INCMRK | 1.24% | $256.75K | 1,972 |
| CSM -N.R CERTHROW | 1.23% | $253.67K | 6,543 |
| JOHNSON & JOHNSONJNJ | 1.22% | $252.50K | 985 |
| ROYALTY PHARMA PLC- CL ARPRX | 1.22% | $251.72K | 4,308 |
| INDIVIOR PHARMACEUTICALS INCINDV | 1.19% | $246.74K | 6,167 |
| PRESTIGE BRANDS HOLDINGS INCPBH | 1.16% | $240.10K | 4,781 |
| COLLEGIUM PHARMACEUTICAL INCCOLL | 1.16% | $238.88K | 6,750 |
| ORGANON & COOGN | 1.15% | $237.90K | 17,557 |
| ELI LILLY & COMPANYLLY | 1.15% | $236.66K | 206 |
| EYEPOINT INCEYPT | 1.13% | $233.37K | 19,051 |
| HARMONY BIOSCIENCES HOLDINGSHRMY | 1.13% | $233.25K | 6,619 |
| SUPERNUS PHARMACEUTICALS INCSUPN | 1.13% | $232.48K | 5,209 |
| PFIZER INCPFE | 1.11% | $229.49K | 9,176 |
| WAVE LIFE SCIENCES LTDWVE | 1.11% | $228.67K | 41,500 |
| PHIBRO ANIMAL HEALTH CORP-APAHC | 1.11% | $228.66K | 6,294 |
| ANI PHARMACEUTICALS INCANIP | 1.10% | $227.42K | 2,870 |
| TARSUS PHARMACEUTICALS INCTARS | 1.10% | $226.24K | 3,832 |
| ZOETIS INCZTS | 1.08% | $223.29K | 2,889 |
| OCULAR THERAPEUTIX INCOCUL | 1.06% | $219.57K | 26,875 |
| XERIS BIOPHARMA HOLDINGS INCXERS | 1.06% | $218.69K | 27,065 |
| RAPPORT THERAPEUTICS INCRAPP | 1.05% | $217.73K | 5,313 |
Holdings from the fund's latest Form N-PORT; expense ratio (net of fee waivers) from the risk/return summary of its prospectus; fund type from Form N-CEN. Prices are end-of-day closes adjusted for splits; total return also reinvests distributions.